V National Conference BIFI, Zaragoza, Febrero 2011
OLGA [email protected]
APPROCHES FOR ANTIVIRAL COMPOUND DEVELOPMENT
V National Conference BIFI, Zaragoza, Febrero 2011
STEPS:
5º EXPLORING NEW TRANSPORT AND SELECTIVE LIBERATION OF DRUGS: We can also try increasing the bioavailability of the compounds we have discovered: Selectively recognition of cells where drug should be preferably released, so adverse effects due to the systemic distribution will be reduced; and an easy way to ensure cell internalization, so compounds active in vitro but not in vivo are rescue.
1º TARGET IDENTIFICATION: A certain protein with biomedical therapy interest which can be inhibited, activated or stabilized by compound binding.
2º ACTIVE COMPOUND SEARCHING: A chemical library with thousands of compounds is used. In order to be efficient, the detection methods must be characterized by High Throughput Screening (HTS). Then, we need fast experimental procedures or multiple simultaneous measurements, or both. From thousands of molecules we must identify a few interesting molecules (hits, lead compounds).
3º CHARACTERIZATION OF THE SELECTED COMPOUNDS: The compounds that have been identified as promising drug candidates are studied in detail using the different biophysical (calorimetric, spectroscopic or crystallographic) techniques available in the facilities of our institute.
4º In Vivo CELL STUDIES: In some cases, the efficiency of the compound can be measured in vivo using a cell system. In other cases in which this is not possible, the toxicity of the compound can be determined using cell cultures.
V National Conference BIFI, Zaragoza, Febrero 2011
1º TARGET IDENTIFICATION
NS3 protein
Protease
HelicaseNTPase
V National Conference BIFI, Zaragoza, Febrero 2011
TARGET CHARACTERIZATION
A/ Structure: Spectroscopic study
By far and near Circular Dichroism, Spectrophotometry and Fluorescence
B/ Zn interaction: Calorimetry (ITC and DSC)
When Zn is removed at pH5 (where no aggregation nor precipitation occurs) the protein unfolds. The binding heat capacity value associated with the binding of Zn and other spectroscopic evidences suggest that this is a “folding by binding” process (Abian et al. Proteins 2009).
C/ Allosteric activation mechanism : Fluorescence
The activity of NS3 protease was measured in the presence and absence of its cofactor pNS4A at different substrate concentration. The cooperativity parameters for the binding of pNS4A and substrate were determined.
V National Conference BIFI, Zaragoza, Febrero 2011
2º HIGH THROUGHPUT SCREENING (HTS)
Two ways for finding interesting molecules:
B/ THERMAL SHIFT SCREENING:
A/ ACTIVITY BASED-SCREENING :
V National Conference BIFI, Zaragoza, Febrero 2011
2º HIGH THROUGHPUT SCREENING (HTS)
A/ ACTIVITY BASED-SCREENING : A molecule inducing an effect must alter protein properties (function, behavior). Methods for detecting function or behavior are requiredOur protein target exhibits protease activity and it can be measured in vitro using a fluorescence (FRET) peptide substrate.
Two ways for finding interesting molecules:
V National Conference BIFI, Zaragoza, Febrero 2011
-500 0 500 1000 1500 2000 2500 3000 3500 4000
200000
300000
400000
500000
600000
700000
800000
900000
Y A
xis
Titl
e
X Axis Title
6B8 4B8 2A10 7C8 6A9 7E8 13C11 6A11 8B3
Example:
B8 D4 E12 G8
-600
-400
-200
0
200
400
600
Y A
xis
Titl
e
X Axis Title
Slope
ResultsKinetic measurements: Vi (initial slope)The ratio of the control positive slopes (X) defines the lower limit(X-2SD). Below this limit the compounds are considered as possible inhibitors.The more lower positive value the best inhibitor compound.
AssayNS3 + Compound from the chemical library + FRET Substrate (RET S1) from Anaspec
Ac - Asp - Glu - Asp(EDANS) - Glu - Glu - Abu - ψ - [COO] - Ala - Ser - Lys(DABCYL) - NH2 Donor Acceptor
A/ SCREENING ACTIVITY BASED:
V National Conference BIFI, Zaragoza, Febrero 2011
2º HIGH THROUGHPUT SCREENING (HTS)
B/ THERMAL SHIFT SCREENING: A molecule inducing an effect must bind to the protein. Methods for detecting binding are requiredIf a ligand binds preferentially to a certain protein conformational state, it stabilizes (increases the population of) such conformational stateTherefore, we can find ligands for a given protein by searching for molecules that increase the conformational stability of the proteinThere are several compounds (ANS, Sypro-Orange, …) which bind the hydrophobic parts of the protein that are exposed during the thermal unfolding and are used as probes.
In our case STABILIZATION OF THE UNFOLDED STATE AT pH5 is studied.
Two ways for finding interesting molecules:
V National Conference BIFI, Zaragoza, Febrero 2011B/ SCREENING THERMAL SHIFT:
20 30 40 50 60 70
0
4000000
8000000
12000000
16000000
20000000
24000000
Control NS3 sin Zn Control NS3 con Zn NS3 sin Zn + compX1 NS3 sin Zn + compX2 NS3 sin Zn + compX3 NS3 sin Zn + compX4 NS3 sin Zn + compX5 NS3 sin Zn + compX6
Flu
ore
sc
en
ce
(A
.U)
Temperature (ºC)
Assay: pH5, with/without EDTA
V National Conference BIFI, Zaragoza, Febrero 2011
3º CHARACTERIZATION OF THE SELECTED COMPOUNDS
A/ Activity:
The activity of the protein was measured at different compound concentrations and so, the inhibition constants (Ki) were determined.
B/ Selectivity:
The activity of human protease (-chymotrypsin) in the presence of the selected compounds was determined.
C/ Binding affinity:
Affinity constants and thermodynamic parameters determination using ITC calorimetry
D/ Crystallographic Structure:
Obtaining the crystallographic structures of the protease with the compound is needed.
V National Conference BIFI, Zaragoza, Febrero 2011
4º In Vivo CELL STUDIES
Bartenschlager, Science 1999, 285(5424)110-3.
V National Conference BIFI, Zaragoza, Febrero 2011
A/ Efficacy in vivo:The luciferase activity from cell culture is measure after 3 days of incubation with the compounds.
B/ Toxicity in vivo:The viability of the cells in the presence of the compounds is measured using XTT. In this cells the replicon system is not present.
0
50
100
150
1 10 1000
50
100
150 Luciferase activity
% A
cti
vid
ad
XT
T
Concentracion compuesto (M)
% A
cti
vid
ad
luc
ife
ras
a Cell viability
V National Conference BIFI, Zaragoza, Febrero 2011
5º EXPLORING NEW TRANSPORT AND SELECTIVE LIBERATION OF DRUGS
AuNP
AuNP1OAV
OAV
OAV
OAV
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
AuNP2
OAV
OAV
OAV
OAV
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
AuNP4A
OAV
OAV
OAV
OAV
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
AuNP4B
= Fabfragment
AuNP3
OAV
OAV
OAV
OAV
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
OA
V
= Internalization peptide
Selective transport
Selective recognition of infected cells
Entry in cells
V National Conference BIFI, Zaragoza, Febrero 2011
FINANCIAL SUPPORTPROYECTOS NACIONALESTITULO DEL PROYECTO: " Nanopartículas multifuncionales para el transporte y liberación selectiva de fármacos frente al virus de la hepatitis C (VHC)” "ENTIDAD FINANCIADORA: Instituto Carlos III DURACION DESDE: 2011 HASTA: 2013CUANTÍA: 83.000€INVESTIGADOR PRINCIPAL: Olga Abian Franco
TITULO DEL PROYECTO: "Proteasa NS3 del virus de la hepatitis C: Identificación y caracterización de inhibidores competitivos y alostéricos"ENTIDAD FINANCIADORA: Ministerio de Ciencia e Innovación DURACION DESDE: 2010 HASTA: 2013CUANTÍA: 90.000€INVESTIGADOR PRINCIPAL: Adrián Velázquez Campoy
TITULO DEL PROYECTO: "Implementación de estudios "in vivo" e "in vitro" de compuestos antiinfecciosos efectivos frente a Helicobacter pylori y el Virus de la Hepatitis C (VHC)"ENTIDAD FINANCIADORA: Instituto Carlos III DURACION DESDE: 2008 HASTA: 2010CUANTÍA: 40.000€INVESTIGADOR PRINCIPAL: Olga Abian Franco
TITULO DEL PROYECTO: “Proteasa NS3 del virus de la hepatitis C: Inhibidores competitivos, alostéricos y bases moleculares de la resistencia a fármacos”ENTIDAD FINANCIADORA: Universidad de Zaragoza DURACION 2010CUANTÍA: 12.700 €INVESTIGADOR PRINCIPAL: Dr. Adrián Velázquez Campoy (Universidad de Zaragoza – BIFI)
PROYECTOS AUTONÓMICOSTITULO DEL PROYECTO: “Equilibrio Conformacional de la proteasa NS3 en virus de la hepatitis C: estado no nativo e identificación de un nuevo tipo de inhibidores alostéricos”ENTIDAD FINANCIADORA: DGA DURACION DESDE: 2009 HASTA: 2011CUANTÍA: 52.000€INVESTIGADOR PRINCIPAL: Adrián Velázquez Campoy
V National Conference BIFI, Zaragoza, Febrero 2011
THANK YOU FOR YOUR ATTENTION!!